anubhai angaldas Securities Pvt. Ltd. Member: BSE - NSE - CDSL

Technology . Transparency . Trust

MARKET

Hot Pursuit
Panacea Biotech gains after bagging supply order from UNICEF
03-Oct-2025 15:17
The company will supply vaccine in 10 and 20 vial presentations during Q2 CY2026 and CY2027, under an order worth $35.65 million (around Rs 315 crore).

Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets.

The company reported a consolidated net profit of Rs 4.05 crore in Q1 FY26 compared with net loss of Rs 15.80 crore in Q1 FY25. Net sales jumped 44.1% YoY to Rs 166.70 crore in Q1 FY26.

Powered by Capital Market - Live News

Attention Investor
As per CDSL communiqué Kindly update your Email ID, Mobile Number & Income Range in CDSL demat Account on or before 31st May 2021, Non Compliance Account will be INACTIVE after 31st May 2021. | Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.  | "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." | "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."    Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of Investors.